Mergers & Acquisitions - Financial, Research


Current filters:


Popular Filters

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023


In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

NeXeption forms new company, Alexar Therapeutics, to develop novel LXR agonist portfolio


US biopharma management company NeXeption says it has secured $21.5 million in Series A financing to…

A-110Alexar TherapeuticsDermatologicalsFinancialMergers & AcquisitionsNeXeptionPharmaceuticalResearch

Aphios spins off Amylon to develop novel Alzheimer’s disease drug


US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies


Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

Biotech industry has "implementation gap" around demonstrating the value of products under development


Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment…

BiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaResearch

DelMar Pharma acquisition; $5.4 million private placement to advance novel cancer therapies


DelMar Pharmaceuticals (OTCQB: BRRY) has announced the successful acquisition, through a share exchange…

DelMar PharmaceuticalsFinancialMergers & AcquisitionsOncologyPharmaceuticalResearchVAL-083

Illumina to buy Verinata; Rusnano et al invest in Marinus


USA-based Illumina (Nasdaq: ILMN), recently the subject of a failed takeover bid by Swiss drug major…

Domain AssociatesFinancialganaxoloneIlluminaMarinus PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceuticalResearchRusNanoVerinata Health

US Biotech scores wins in November, despite global economic turmoil, says Burrill


Economic and political worries in Europe and the USA fuelled another month of wild gyrations in the stock…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaResearch

Back to top